866-997-4948(US-Canada Toll Free)

Malignant Pleural Mesothelioma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 100 Pages


Global Markets Directs, \'Malignant Pleural Mesothelioma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Malignant Pleural Mesothelioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma. 

Malignant Pleural Mesothelioma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Malignant Pleural Mesothelioma.
  • A review of the Malignant Pleural Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Malignant Pleural Mesothelioma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy


  • Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Malignant Pleural Mesothelioma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Malignant Pleural Mesothelioma 9
Malignant Pleural Mesothelioma Therapeutics under Development by Companies 11
Malignant Pleural Mesothelioma Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Malignant Pleural Mesothelioma Therapeutics - Products under Development by Companies 17
Malignant Pleural Mesothelioma Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Malignant Pleural Mesothelioma Therapeutics Development 19
Biogen Idec Inc. 19
AstraZeneca PLC 20
Merck & Co., Inc. 21
Plexxikon Inc. 22
Pfizer Inc. 23
Aduro BioTech 24
AEterna Zentaris Inc. 25
Bionomics Limited 26
University of Pennsylvania 27
Morphotek, Inc. 28
CanBas Co., Ltd. 29
MolMed S.p.A. 30
Polaris Group 31
Malignant Pleural Mesothelioma - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
cediranib maleate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NGR-hTNF - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BG-00001 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
amatuximab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CBP-501 + [cisplatin] + [pemetrexed disodium] - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 49
adenoviral mediated interferon beta - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PLX-3397 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ADI-PEG 20 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
vorinostat - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
NGR-hTNF + [gemcitabine hydrochloride] - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
NGR-hTNF + [vinorelbine tartrate] - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PF-03446962 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
amatuximab + [cisplatin] + [pemetrexed disodium] - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
icelecoxib + [decitabine] + [depsipeptide] - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 69
romidepsin + alvocidib - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
BNC-105-P - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
interferon alfa-2b - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
bortezomib + [oxaliplatin] - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
cetuximab + [carboplatin] + [cisplatin] + [pemetrexed] - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Autologous Tumor Cell Vaccine + [celecoxib] + [Iscomatrix] - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
pemetrexed disodium + [cisplatin] - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Autologous Mesothelin Redirected T Cells - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SS1P + [cisplatin] + [pemetrexed disodium] - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
CRS-207 + Cisplatin + Pemetrexed - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Malignant Pleural Mesothelioma Therapeutics - Drug Profile Updates 82
Malignant Pleural Mesothelioma Therapeutics - Discontinued Products 91
Malignant Pleural Mesothelioma Therapeutics - Dormant Products 92
Malignant Pleural Mesothelioma - Product Development Milestones 93
Featured News & Press Releases 93
Nov 12, 2012: Morphotek\'s Amatuximab Receives FDA Orphan Drug Designation For Treatment Of Malignant Pleural Mesothelioma 93
Aug 24, 2012: US Court Of Appeals Upholds Validity Of Lilly\'s Alimta Compound Patent 93
Jun 04, 2012: CanBas\'s CBP501 Meets Primary Endpoint In Phase II Study Of Malignant Pleural Mesothelioma 93
Jun 04, 2012: MolMed Presents Long-Term Follow Up Data From Phase II Mesothelioma Trial Of NGR-hTNF At ASCO 94
Jun 01, 2012: Bionomics To Present Clinical Trial Data Of BNC105 At ASCO Meeting 95
May 31, 2012: Aeterna Zentaris Announces Pubication Of New Data On Perifosine In Plos One 96
Nov 01, 2011: Canbas Enrolls Last Patient In Phase II Trial Of CBP501 As First-Line Treatment Of Malignant Pleural Mesothelioma 96
Sep 27, 2011: MolMed Presents Data From New Clinical Trial On NGR-Htnf At High Doses At European Multidisciplinary Cancer Congress 97
Sep 23, 2011: Merck\'s ZOLINZA Fails Primary Endpoint In Phase III Mesothelioma Study 97
Apr 13, 2010: Molmed Starts Phase III Trial Of NGR-hTNF In Mesothelioma 98

Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100

List of Table


Number of Products Under Development for Malignant Pleural Mesothelioma, H1 2013 9
Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Investigation by Universities/Institutes, H1 2013 13
Comparative Analysis by Late Stage Development, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Early Clinical Stage Development, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Investigation by Universities/Institutes, H1 2013 18
Biogen Idec Inc., H1 2013 19
AstraZeneca PLC, H1 2013 20
Merck & Co., Inc., H1 2013 21
Plexxikon Inc., H1 2013 22
Pfizer Inc., H1 2013 23
Aduro BioTech, H1 2013 24
AEterna Zentaris Inc., H1 2013 25
Bionomics Limited, H1 2013 26
University of Pennsylvania, H1 2013 27
Morphotek, Inc., H1 2013 28
CanBas Co., Ltd., H1 2013 29
MolMed S.p.A., H1 2013 30
Polaris Group, H1 2013 31
Assessment by Monotherapy Products, H1 2013 32
Assessment by Combination Products, H1 2013 33
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Stage and Molecule Type, H1 2013 37
Malignant Pleural Mesothelioma Therapeutics - Drug Profile Updates 82
Malignant Pleural Mesothelioma Therapeutics - Discontinued Products 91
Malignant Pleural Mesothelioma Therapeutics - Dormant Products 92

List of Chart


Number of Products under Development for Malignant Pleural Mesothelioma, H1 2013 9
Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 13
Late Stage Products, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Early Clinical Stage Products, H1 2013 16
Assessment by Monotherapy Products, H1 2013 32
Assessment by Combination Products, H1 2013 33
Assessment by Route of Administration, H1 2013 34
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Molecule Type, H1 2013 36
Assessment by Stage and Molecule Type, H1 2013 37

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *